Cargando…

Pemafibrate, a New Selective PPARα Modulator: Drug Concept and Its Clinical Applications for Dyslipidemia and Metabolic Diseases

PURPOSE OF REVIEW: Reduction of serum low-density lipoprotein cholesterol (LDL-C) levels by statins, ezetimibe and proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors has been shown to significantly reduce cardiovascular events risk. However, fasting and postprandial hypertriglyceridemi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yamashita, Shizuya, Masuda, Daisaku, Matsuzawa, Yuji
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2020
Materias:	Nonstatin Drugs (R. Carmena, Section Editor)
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6978439/ https://www.ncbi.nlm.nih.gov/pubmed/31974794 http://dx.doi.org/10.1007/s11883-020-0823-5

Ejemplares similares

Clinical Applications of a Novel Selective PPARα Modulator, Pemafibrate, in Dyslipidemia and Metabolic Diseases
por: Yamashita, Shizuya, et al.
Publicado: (2019)

Current Role of Lipoprotein Apheresis
por: Thompson, Gilbert, et al.
Publicado: (2019)

Emerging Evidence that ApoC-III Inhibitors Provide Novel Options to Reduce the Residual CVD
por: Taskinen, Marja-Riitta, et al.
Publicado: (2019)

Novel Selective PPARα Modulator Pemafibrate for Dyslipidemia, Nonalcoholic Fatty Liver Disease (NAFLD), and Atherosclerosis †
por: Yamashita, Shizuya, et al.
Publicado: (2023)

A Novel Selective PPARα Modulator (SPPARMα), K-877 (Pemafibrate), Attenuates Postprandial Hypertriglyceridemia in Mice
por: Sairyo, Masami, et al.
Publicado: (2018)

Erratum:A Novel Selective PPARα Modulator (SPPARMα), K-877 (Pemafibrate), Attenuates Postprandial Hypertriglyceridemia in Mice
por: Sairyo, Masami, et al.
Publicado: (2018)

Selective Peroxisome Proliferator-Activated Receptor Alpha Modulators (SPPARMα) in the Metabolic Syndrome: Is Pemafibrate Light at the End of the Tunnel?
por: Fruchart, Jean-Charles, et al.
Publicado: (2021)

Marked effects of novel selective peroxisome proliferator-activated receptor α modulator, pemafibrate in severe hypertriglyceridemia: preliminary report
por: Iitake, Chie, et al.
Publicado: (2020)

RNA Silencing in the Management of Dyslipidemias
por: Henney, Neil C., et al.
Publicado: (2021)

Distinct Differences in Lipoprotein Particle Number Evaluation between GP-HPLC and NMR: Analysis in Dyslipidemic Patients Administered a Selective PPARα Modulator, Pemafibrate
por: Yamashita, Shizuya, et al.
Publicado: (2021)

Cultural Barriers in the Treatment of Dyslipidemia: A Survey of Japanese Physician Attitudes
por: Yamashita, Shizuya, et al.
Publicado: (2019)

Selective Peroxisome Proliferator–Activated Receptor Alpha Modulators (SPPARMα): New Opportunities to Reduce Residual Cardiovascular Risk in Chronic Kidney Disease?
por: Fruchart, Jean-Charles, et al.
Publicado: (2020)

Rare Treatments for Rare Dyslipidemias: New Perspectives in the Treatment of Homozygous Familial Hypercholesterolemia (HoFH) and Familial Chylomicronemia Syndrome (FCS)
por: D’Erasmo, Laura, et al.
Publicado: (2021)

Nutraceuticals in the Management of Dyslipidemia: Which, When, and for Whom? Could Nutraceuticals Help Low-Risk Individuals with Non-optimal Lipid Levels?
por: Cicero, Arrigo F. G., et al.
Publicado: (2021)

Niacin Alternatives for Dyslipidemia: Fool’s Gold or Gold Mine? Part II: Novel Niacin Mimetics
por: Goel, Harsh, et al.
Publicado: (2016)

Niacin Alternatives for Dyslipidemia: Fool’s Gold or Gold Mine? Part I: Alternative Niacin Regimens
por: Dunbar, Richard L., et al.
Publicado: (2016)

New Horizons for Probucol, an Old, Mysterious Drug
por: Yamashita, Shizuya, et al.
Publicado: (2021)

Management of Dyslipidemia in Patients with Non-Alcoholic Fatty Liver Disease
por: Martin, Anna, et al.
Publicado: (2022)

Effect of fenofibrate and selective PPARα modulator (SPPARMα), pemafibrate on KATP channel activity and insulin secretion
por: Kitamura, Shigeki, et al.
Publicado: (2023)

Lomitapide–a Microsomal Triglyceride Transfer Protein Inhibitor for Homozygous Familial Hypercholesterolemia
por: Stefanutti, Claudia
Publicado: (2020)

The Role of Nutraceuticals in the Optimization of Lipid-Lowering Therapy in High-Risk Patients with Dyslipidaemia
por: Penson, Peter E., et al.
Publicado: (2020)

Monoclonal Antibodies in the Management of Familial Hypercholesterolemia: Focus on PCSK9 and ANGPTL3 Inhibitors
por: Pirillo, Angela, et al.
Publicado: (2021)

Oral Lipid-Lowering Treatments Beyond Statins: Too Old and Outdated or Still Useful?
por: Parhofer, Klaus G.
Publicado: (2021)

Managing of Dyslipidaemia Characterized by Accumulation of Triglyceride-Rich Lipoproteins
por: Visser, Jolien, et al.
Publicado: (2022)

Long-Term Efficacy and Safety of Pemafibrate, a Novel Selective Peroxisome Proliferator-Activated Receptor-α Modulator (SPPARMα), in Dyslipidemic Patients with Renal Impairment
por: Yokote, Koutaro, et al.
Publicado: (2019)

Triglyceride Level and Cardiovascular Risk Reduction Using Pemafibrate Compared with Fibrates
por: Masuda, Daisaku
Publicado: (2023)

Effects of a novel selective peroxisome proliferator‐activated receptor‐α modulator, pemafibrate, on hepatic and peripheral glucose uptake in patients with hypertriglyceridemia and insulin resistance
por: Matsuba, Ikuro, et al.
Publicado: (2018)

Thyroid Hormone Mimetics: the Past, Current Status and Future Challenges
por: Elbers, L.P.B., et al.
Publicado: (2016)

Bempedoic Acid (ETC-1002): an Investigational Inhibitor of ATP Citrate Lyase
por: Bilen, Ozlem, et al.
Publicado: (2016)

Antioxidants in the Fight Against Atherosclerosis: Is This a Dead End?
por: Toledo-Ibelles, Paola, et al.
Publicado: (2018)

A novel selective PPARα modulator, pemafibrate promotes ischemia-induced revascularization through the eNOS-dependent mechanisms
por: Kawanishi, Hiroshi, et al.
Publicado: (2020)

Pemafibrate, a selective PPARα modulator, prevents non-alcoholic steatohepatitis development without reducing the hepatic triglyceride content
por: Sasaki, Yusuke, et al.
Publicado: (2020)

Event Monitoring and Evaluation by Community Pharmacists in Japan: A Pilot Study on Fenofibrate and Pemafibrate
por: Takahashi, Masao, et al.
Publicado: (2022)

Efficacy and Safety of Pemafibrate, a Novel Selective Peroxisome Proliferator-Activated Receptor α Modulator (SPPARMα): Pooled Analysis of Phase 2 and 3 Studies in Dyslipidemic Patients with or without Statin Combination
por: Yamashita, Shizuya, et al.
Publicado: (2019)

Functional and Structural Insights into Human PPARα/δ/γ Subtype Selectivity of Bezafibrate, Fenofibric Acid, and Pemafibrate
por: Honda, Akihiro, et al.
Publicado: (2022)

Enhanced Intestinal Absorption of Cholesterol along with Increased Chylomicron Remnants for De novo Progression of Coronary Stenosis
por: Masuda, Daisaku, et al.
Publicado: (2017)

Postprandial Hyperlipidemia and Remnant Lipoproteins
por: Masuda, Daisaku, et al.
Publicado: (2017)

Postprandial Glucose and Triglyceride Increases Along with the Endothelial Malfunction were Attenuated by the Administration of SGLT2 Inhibitor, Empagliflozin
por: Masuda, Daisaku, et al.
Publicado: (2020)

Serum HDL-Cholesterol Level Does Not Influence Cardiovascular Event Rate under Sufficient Lowering of LDL-Cholesterol by Pitavatatin in Patients with Stable Coronary Artery Disease
por: Masuda, Daisaku, et al.
Publicado: (2022)

Elucidation of Molecular Mechanism of a Selective PPARα Modulator, Pemafibrate, through Combinational Approaches of X-ray Crystallography, Thermodynamic Analysis, and First-Principle Calculations
por: Kawasaki, Mayu, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_mn8i3vj5bfvq7jrdpaseban1l6